TDG Form 4: 518 director options at $1,291.97 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TransDigm Group (TDG) filed a Form 4 for director Jane Cronin reporting a grant of stock options on 11/04/2025. The award covers 518 options with an exercise price of $1,291.97 per share.
The options vest 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. Following this transaction, 518 derivative securities were beneficially owned, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
CRONIN JANE M.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 518 | $0.00 | -- |
Holdings After Transaction:
Stock Option — 518 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did TransDigm (TDG) disclose in this Form 4?
A director, Jane Cronin, received 518 stock options at an exercise price of $1,291.97 per share on 11/04/2025.
What is the vesting schedule for the TDG options?
They vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets.
When do these TransDigm options expire?
The options expire on 11/04/2035.
How many derivative securities were owned after the transaction?
518 derivative securities were beneficially owned following the reported transaction.
What is the ownership form of the reported options?
The ownership form is Direct (D).
Who is the reporting person in this filing?
Jane Cronin, as indicated by the signature by attorney-in-fact.